131 related articles for article (PubMed ID: 26330244)
1. Hypoxia-reperfusion affects osteogenic lineage and promotes sickle cell bone disease.
Dalle Carbonare L; Matte' A; Valenti MT; Siciliano A; Mori A; Schweiger V; Zampieri G; Perbellini L; De Franceschi L
Blood; 2015 Nov; 126(20):2320-8. PubMed ID: 26330244
[TBL] [Abstract][Full Text] [Related]
2. Osteoclast activation and sickle bone disease.
Gordeuk VR
Blood; 2015 Nov; 126(20):2259-60. PubMed ID: 26564903
[No Abstract] [Full Text] [Related]
3. Mechanisms of Bone Impairment in Sickle Bone Disease.
Giordano P; Urbano F; Lassandro G; Faienza MF
Int J Environ Res Public Health; 2021 Feb; 18(4):. PubMed ID: 33668588
[TBL] [Abstract][Full Text] [Related]
4. Preclinical evaluation of zoledronate using an in vitro mimetic cellular model for breast cancer metastatic bone disease.
Dedes PG; Kanakis I; Gialeli Ch; Theocharis AD; Tsegenidis T; Kletsas D; Tzanakakis GN; Karamanos NK
Biochim Biophys Acta; 2013 Jun; 1830(6):3625-34. PubMed ID: 23395844
[TBL] [Abstract][Full Text] [Related]
5. Lumichrome inhibits osteoclastogenesis and bone resorption through suppressing RANKL-induced NFAT activation and calcium signaling.
Liu C; Cao Z; Zhang W; Tickner J; Qiu H; Wang C; Chen K; Wang Z; Tan R; Dong S; Xu J
J Cell Physiol; 2018 Nov; 233(11):8971-8983. PubMed ID: 29904917
[TBL] [Abstract][Full Text] [Related]
6. Zoledronate Enhances Osteocyte-Mediated Osteoclast Differentiation by IL-6/RANKL Axis.
Kim HJ; Kim HJ; Choi Y; Bae MK; Hwang DS; Shin SH; Lee JY
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30909508
[TBL] [Abstract][Full Text] [Related]
7. Coenzyme q10 regulates osteoclast and osteoblast differentiation.
Moon HJ; Ko WK; Jung MS; Kim JH; Lee WJ; Park KS; Heo JK; Bang JB; Kwon IK
J Food Sci; 2013 May; 78(5):H785-891. PubMed ID: 23582186
[TBL] [Abstract][Full Text] [Related]
8. WHI-131 Promotes Osteoblast Differentiation and Prevents Osteoclast Formation and Resorption in Mice.
Cheon YH; Kim JY; Baek JM; Ahn SJ; Jun HY; Erkhembaatar M; Kim MS; Lee MS; Oh J
J Bone Miner Res; 2016 Feb; 31(2):403-15. PubMed ID: 26255791
[TBL] [Abstract][Full Text] [Related]
9. Macrolactin F inhibits RANKL-mediated osteoclastogenesis by suppressing Akt, MAPK and NFATc1 pathways and promotes osteoblastogenesis through a BMP-2/smad/Akt/Runx2 signaling pathway.
Li L; Sapkota M; Gao M; Choi H; Soh Y
Eur J Pharmacol; 2017 Nov; 815():202-209. PubMed ID: 28919027
[TBL] [Abstract][Full Text] [Related]
10. RANKL coordinates cell cycle withdrawal and differentiation in osteoclasts through the cyclin-dependent kinase inhibitors p27KIP1 and p21CIP1.
Sankar U; Patel K; Rosol TJ; Ostrowski MC
J Bone Miner Res; 2004 Aug; 19(8):1339-48. PubMed ID: 15231022
[TBL] [Abstract][Full Text] [Related]
11. Role of zoledronic acid in oncolytic virotherapy: Promotion of antitumor effect and prevention of bone destruction.
Yamakawa Y; Tazawa H; Hasei J; Osaki S; Omori T; Sugiu K; Komatsubara T; Uotani K; Fujiwara T; Yoshida A; Kunisada T; Urata Y; Kagawa S; Ozaki T; Fujiwara T
Cancer Sci; 2017 Sep; 108(9):1870-1880. PubMed ID: 28685948
[TBL] [Abstract][Full Text] [Related]
12. Bisphosphonates inhibit osteosarcoma-mediated osteolysis via attenuation of tumor expression of MCP-1 and RANKL.
Ohba T; Cole HA; Cates JM; Slosky DA; Haro H; Ando T; Schwartz HS; Schoenecker JG
J Bone Miner Res; 2014 Jun; 29(6):1431-45. PubMed ID: 24443409
[TBL] [Abstract][Full Text] [Related]
13. Targeting of the osteoclastogenic RANKL-RANK axis prevents osteoporotic bone loss and soft tissue calcification in coxsackievirus B3-infected mice.
Lee K; Kim H; Park HS; Kim KJ; Song H; Shin HI; Kim HS; Seo D; Kook H; Ko JH; Jeong D
J Immunol; 2013 Feb; 190(4):1623-30. PubMed ID: 23303667
[TBL] [Abstract][Full Text] [Related]
14. Elevated Gα11 expression in osteoblast lineage cells promotes osteoclastogenesis and leads to enhanced trabecular bone accrual in response to pamidronate.
Dela Cruz A; Grynpas MD; Mitchell J
Am J Physiol Endocrinol Metab; 2016 May; 310(10):E811-20. PubMed ID: 27006198
[TBL] [Abstract][Full Text] [Related]
15. Live imaging of osteoclast inhibition by bisphosphonates in a medaka osteoporosis model.
Yu T; Witten PE; Huysseune A; Buettner A; To TT; Winkler C
Dis Model Mech; 2016 Feb; 9(2):155-63. PubMed ID: 26704995
[TBL] [Abstract][Full Text] [Related]
16. Lanthanum carbonate prevents accelerated medial calcification in uremic rats: role of osteoclast-like activity.
Che Y; Bing C; Akhtar J; Tingting Z; Kezhou Y; Rong W
J Transl Med; 2013 Dec; 11():308. PubMed ID: 24330832
[TBL] [Abstract][Full Text] [Related]
17. Depletion of Intestinal Microbiome Partially Rescues Bone Loss in Sickle Cell Disease Male Mice.
Tavakoli S; Xiao L
Sci Rep; 2019 Jun; 9(1):8659. PubMed ID: 31209247
[TBL] [Abstract][Full Text] [Related]
18. Secreted frizzled-related protein-1 inhibits RANKL-dependent osteoclast formation.
Häusler KD; Horwood NJ; Chuman Y; Fisher JL; Ellis J; Martin TJ; Rubin JS; Gillespie MT
J Bone Miner Res; 2004 Nov; 19(11):1873-81. PubMed ID: 15476588
[TBL] [Abstract][Full Text] [Related]
19. Loss of Bone in Sickle Cell Trait and Sickle Cell Disease Female Mice Is Associated With Reduced IGF-1 in Bone and Serum.
Xiao L; Andemariam B; Taxel P; Adams DJ; Zempsky WT; Dorcelus V; Hurley MM
Endocrinology; 2016 Aug; 157(8):3036-46. PubMed ID: 27171384
[TBL] [Abstract][Full Text] [Related]
20. Bisphosphonates hinder osteoblastic/osteoclastic differentiation in the maxillary sinus mucosa-derived stem cells.
Zhang J; Park J; Lee JW; Kwon YD; Kim EC
Clin Oral Investig; 2018 Jun; 22(5):1933-1943. PubMed ID: 29188452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
